J. Peglion

发表

Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1

G. Ferry, F. Adam, D. Lawrence, 2016, Scientific Reports.

Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.

C Dacquet, M. Millan, A. Gobert, 1995, The Journal of pharmacology and experimental therapeutics.

Anti-Ischemic Effects of Ivabradine, a Selective Heart Rate-Reducing Agent, in Exercise-Induced Myocardial Ischemia in Pigs

J. Vilaine, J. Péglion, J. Bidouard, 2003, Journal of cardiovascular pharmacology.

Electrophysiological effects of S 16257, a novel sino‐atrial node modulator, on rabbit and guinea‐pig cardiac preparations: comparison with UL‐FS 49

J. Prost, J. Vilaine, J. Péglion, 1994, British journal of pharmacology.

In vivo quantification of myocardial dihydropyridine binding sites: a PET study in dogs.

C. Crouzel, F. Dollé, H. Valette, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.

M. Millan, D. Cussac, A. Gobert, 2000, The Journal of pharmacology and experimental therapeutics.

S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

M. Papp, M. Millan, J. Péglion, 2001, The Journal of pharmacology and experimental therapeutics.

S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.

R. Schreiber, R. Jaffard, S. Hjorth, 1997, The Journal of pharmacology and experimental therapeutics.

S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole

M. Millan, J. Brotchie, A. Gobert, 2004, Journal of Pharmacology and Experimental Therapeutics.

Tetracyclic analogues of [+]-S 14297: Synthesis and determination of affinity and selectivity at cloned human dopamine D3 vs D2 receptors

M. Millan, V. Audinot, J. Péglion, 1997 .

S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole

M. Millan, D. Cussac, A. Gobert, 2004, Journal of Pharmacology and Experimental Therapeutics.

S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

M. Millan, A. Gobert, J. Rivet, 2001, The Journal of pharmacology and experimental therapeutics.

S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole

M. Papp, M. Millan, T. Sharp, 2004, Journal of Pharmacology and Experimental Therapeutics.

Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.

M. Millan, A. Gobert, J. Rivet, 1995, The Journal of pharmacology and experimental therapeutics.

5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists.

M. Millan, G. Lavielle, J. Péglion, 1997, European journal of pharmacology.

[3H](+)S 14297: A novel, selective radioligand at cloned human dopamine D3 receptors

M. Millan, A. Newman-Tancredi, V. Audinot, 1995, Neuropharmacology.

Use‐dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity

P. Chomarat, F. Cogé, J. Boutin, 2007, British journal of pharmacology.

S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.

R. Schreiber, M. Millan, A. Gobert, 1998, The Journal of pharmacology and experimental therapeutics.

Improvement in the selectivity and metabolic stability of the serotonin 5-HT1A ligand, S 15535: A series of cis- and trans-2-(arylcycloalkylamine) 1-indanols

M. Millan, A. Newman-Tancredi, J. Péglion, 2002 .

Synthesis of benzocyclobutenes by palladium-catalyzed C-H activation of methyl groups: method and mechanistic study.

E. Clot, J. Hitce, J. Péglion, 2008, Journal of the American Chemical Society.

The Serotonin1A Receptor Partial Agonist S15535 [4-(Benzodioxan-5-yl)1-(indan-2-yl)piperazine] Enhances Cholinergic Transmission and Cognitive Function in Rodents: A Combined Neurochemical and Behavioral Analysis

R. Jaffard, M. Millan, A. Gobert, 2004, Journal of Pharmacology and Experimental Therapeutics.

S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively.

M. Millan, A. Gobert, J. Rivet, 1993, European journal of pharmacology.

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.

M. Millan, C. Mannoury la Cour, D. Dupuis, 2009, Bioorganic & medicinal chemistry letters.

Sigma ligand S14905 and locomotor activity in mice

Michel Bourin, Richard Payeur, M. Bourin, 1995, European Neuropsychopharmacology.

S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors: II. Functional Profile and a Multiparametric Comparison with Haloperidol, Clozapine, and 11 Othe

M. Millan, J. Rivet, A. Newman-Tancredi, 2000 .

Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: Interaction studies with citalopram

M. Millan, J. Péglion, R. Gannon, 2009, European Neuropsychopharmacology.